Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SGHT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSight Sciences wins $55.4M patent verdict against Alcon plus 10% royalty, but payment uncertain
Filed April 23, 2026 · Period ending April 22, 2026 · ~1 min read
Key Changes
-
high
Court awarded $55.4M in damages for Alcon's willful infringement of three Hydrus Microstent patents, covering past sales through March 2026 plus interest. No payment until appeals exhausted.
Item 8.01 view on EDGAR → -
high
Ongoing 10% royalty on all Hydrus revenue awarded through patent expiration, creating potential recurring revenue stream if judgment survives appeal process.
Item 8.01 view on EDGAR → -
high
Alcon can appeal to Federal Circuit, delaying any payment potentially for years. Separate patent reexamination proceedings could invalidate claims and eliminate collection rights entirely.
Item 8.01 view on EDGAR → -
medium
Court affirmed jury finding that Alcon willfully infringed valid patent claims, validating Sight Sciences' intellectual property position in glaucoma device market.
Item 8.01 view on EDGAR →
Summary
Sight Sciences secured a major legal victory with a $55.4 million judgment against competitor Alcon for patent infringement related to the Hydrus Microstent glaucoma device. The court found Alcon willfully violated three valid patents and awarded damages covering sales from product launch through March 2026, plus a 10% ongoing royalty on future Hydrus revenue until patent expiration.
This validates the company's intellectual property and could generate significant cash flow. However, investors should temper expectations: Sight Sciences won't see a dollar until Alcon exhausts its appeal rights or the appeal window closes, which could take years. More concerning, Alcon has launched separate patent reexamination proceedings attempting to invalidate the same claims.
If those succeed before the appeal concludes, the entire judgment could evaporate. Watch for Alcon's appeal filing and any updates on the reexamination proceedings. The company's ability to actually collect this award remains highly uncertain, making this more of a potential future catalyst than an immediate financial benefit.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Court awarded Sight Sciences $55.4M in patent infringement damages plus 10% ongoing royalty against Alcon, subject to appeal.
Added in current filing · verify on EDGAR →
The Final Judgment upheld the trial jury’s findings that the Patent claims asserted by the Company at trial were valid and were willfully infringed by Alcon.
The U.S. District Court for the District of Delaware entered final judgment affirming that Alcon willfully infringed three of Sight Sciences' patents related to the Hydrus Microstent. This validates the company's intellectual property claims and establishes Alcon's liability.
Added in current filing · verify on EDGAR →
The Final Judgment also awarded total monetary damages to the Company of $55.4 million. This award is inclusive of: (i) $34.0 million in past damages for the period from the first commercial sale of Hydrus through April 26, 2024, the date the trial jury rendered its verdict (the “Verdict Date”), (ii) $14.7 million in supplemental damages for the period from the Verdict Date through March 31, 2026, and (iii) $6.8 million in pre-judgment and post-judgment interest through April 17, 2026.
The court awarded Sight Sciences $55.4 million in total damages covering past infringement, supplemental damages through March 2026, and interest. This represents significant potential cash inflow if the judgment survives appeal.
Added in current filing · verify on EDGAR →
In addition, the Final Judgment awarded the Company an ongoing royalty of 10% of Hydrus revenue through the date of expiration of the last of the Patents.
Beyond the one-time damages, Sight Sciences was awarded a 10% ongoing royalty on all Hydrus revenue until the patents expire. This creates a recurring revenue stream from a competitor's product if the judgment is upheld.
Added in current filing · verify on EDGAR →
Absent settlement, no monetary damages will be received by the Company unless and until (i) Alcon exhausts its rights to appeal to the United States Court of Appeals for the Federal Circuit and the appeals court affirms a judgment in the Company’s favor, or (ii) the time for filing an appeal has passed.
The judgment is subject to appeal by Alcon, and Sight Sciences will not receive any payment until appeals are exhausted or the appeal period expires. This means the $55.4 million award and ongoing royalties remain uncertain and could be years away or potentially overturned.
Added in current filing · verify on EDGAR →
In addition, if an adverse, final and non-appealable judgment from one or more of the ex parte reexamination proceedings initiated by Alcon (seeking to invalidate the Patent claims we asserted at trial) is entered by the Federal Circuit Court of Appeals before a favorable final and non-appealable judgment from the Litigation is entered by that same appeals court, it could negatively affect the Company’s ability to collect on the Final Judgment.
Alcon has initiated separate patent reexamination proceedings attempting to invalidate the asserted patent claims. If those proceedings succeed before the litigation appeal concludes, it could eliminate Sight Sciences' ability to collect the awarded damages and royalties.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify